^
    15h
    INCB 84344-102: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Incyte Biosciences International Sàrl | Trial completion date: Jan 2026 --> Feb 2028 | Trial primary completion date: Jan 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RET (Ret Proto-Oncogene) • FGFR (Fibroblast Growth Factor Receptor) • BLM (BLM RecQ Like Helicase)
    |
    EGFR mutation • KIT mutation • FGFR mutation • RET mutation
    |
    Iclusig (ponatinib)
    16h
    Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=80, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cytarabine • Vanflyta (quizartinib) • idarubicin hydrochloride • cladribine • Starasid (cytarabine ocfosfate)
    17h
    Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    24h
    High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology (clinicaltrials.gov)
    P=N/A, N=124, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Mar 2026
    Enrollment closed • Trial completion date
    24h
    NCI-2019-08946: CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=46 --> 21 | Trial primary completion date: Jan 2027 --> Jun 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    1d
    VENETACIBLE: Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven (clinicaltrials.gov)
    P=N/A, N=20, Completed, Centre Hospitalier Universitaire de Nice | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Mar 2025
    Trial completion • Trial completion date
    |
    Venclexta (venetoclax) • azacitidine
    2d
    A proteogenomic gene signature defines prognostic subgroups highlighting PI3K/AKT/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignancies. (PubMed, Cell Commun Signal)
    Together, our findings revealed shared molecular features across MPN and AML, identified a prognostic gene signature for risk stratification, and provided rationale for PI3K/mTOR inhibition as a promising therapeutic strategy in myeloid malignancies.
    Journal • Gene Signature
    |
    CDCP1 (CUB Domain Containing Protein 1)
    |
    omipalisib (GSK2126458)
    2d
    NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia. (PubMed, Leuk Lymphoma)
    Proteomic profiling showed that NAMPT inhibition with KPT-9274 induced adaptive upregulation of BCL2, an anti-apoptotic protein, highlighting a survival mechanism...Additionally, NAMPT inhibition reduced PARP activity and impaired DNA repair pathways, sensitizing AML cells to cytarabine and hypomethylating agents. Together, these results demonstrate that NAMPT inhibition both potentiates venetoclax activity and enhances the cytotoxic effects of standard chemotherapies by targeting metabolic and DNA repair vulnerabilities. These findings provide strong preclinical support for evaluating NAMPT and BCL2 dual inhibition strategies in future AML clinical trials.
    Journal • PARP Biomarker • IO biomarker
    |
    MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • NAMPT (Nicotinamide Phosphoribosyltransferase)
    |
    Venclexta (venetoclax) • cytarabine • padnarsertib (KPT-9274)
    2d
    Sepsis and mucositis-related biomarkers in adult hematologic patients with febrile neutropenia. (PubMed, Leuk Lymphoma)
    Patients with severe sepsis had higher levels of PCT and lower levels of I-FABP. In conclusion, measurement of mucosa-related biomarkers might help predict the course of FN.
    Journal
    |
    TJP1 (Tight Junction Protein 1) • CRP (C-reactive protein)
    3d
    Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia. (PubMed, Cell Cycle)
    Cytarabine (ara-C) and fludarabine (F-ara-A) are key drugs in leukaemia treatment. Mechanistically, IMPDHi depleted allosteric SAMHD1 activators GTP and dGTP, thereby increasing active triphosphate metabolites in SAMHD1-proficient, but not SAMHD1-deficient, cells. Our findings suggest that the addition of IMPDHi to ara-C and F-ara-A may have therapeutic benefits in some AML cases.
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    cytarabine • fludarabine IV
    3d
    A cancer-testis antigen signature for predicting prognosis and response to immunotherapy in acute myeloid leukemia. (PubMed, Medicine (Baltimore))
    Drug sensitivity profiling highlighted differential therapeutic vulnerabilities between risk groups. This study established and validated a novel CTA-based prognostic tool for prognostic stratification and personalized treatment guidance in AML, bridging molecular insights with clinical applications.
    Journal • IO biomarker
    |
    ACRBP (Acrosin Binding Protein) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • KDM5B (Lysine Demethylase 5B) • SPAG1 (Sperm Associated Antigen 1)